NCT00897923

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 17 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future. PURPOSE: This study is measuring radiolabeled white blood cells in patients with non-Hodgkin's lymphoma.

Detailed description

OBJECTIVES: * Determine the number of indium In 111-labeled peripheral blood mononuclear cells (PBMCs) and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into lymphoma tumors prior to therapy in patients with non-Hodgkin's lymphoma. * Compare the number of PBMC and PMNL trafficking prior to vs after therapy in these patients. * Compare, preliminarily, the number of in vivo baseline (i.e., pre-therapy) trafficking of PBMCs vs PMNLs in these patients. * Gather important data regarding the inter- and intra-patient variability of effector cell trafficking into these tumors. * Assess the relationship between response at 8-12 weeks and the magnitude of baseline effector cell trafficking or the magnitude of post-rituximab effector cell trafficking in these patients. OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups. * Group I: Patients receive autologous indium In 111 (\^111In)-labeled peripheral blood mononuclear cells on day 0. * Group II: Patients receive autologous \^111In-labeled polymorphonuclear leukocytes on day 0. In both groups, patients undergo blood collection on day 0. Patients then undergo full-body single-photon emission-computed tomography (SPECT) scan 4 hours after cell infusion and on day 2. The labeling and imaging process may be repeated after at least 1 course of anticancer treatment. Cellular uptake is measured by reader/visual interpretation, a semiquantitative grading system, and tumor-to-background uptake ratios. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.

Conditions

• Lymphoma
• Small Intestine Cancer

Interventions

Type	Name	Description
PROCEDURE	radionuclide imaging
RADIATION	indium In 111-labeled autologous peripheral blood mononuclear cells
RADIATION	indium In 111-labeled autologous polymorphonuclear leukocytes

Timeline

• Start date: 2003-09-01
• Primary completion: 2012-02-10
• Completion: 2012-02-10
• First posted: 2009-05-12
• Last updated: 2017-03-22

Locations

2 sites across 1 country: United States